Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer.

被引：0
|
作者：
Overmoyer, B
Silverman, P
Leeming, R
Shenk, R
Lyons, J
Jesberger, J
Hartman, P
Dumadag, L
Chen, H
机构：
[1] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[2] NCI, CTEP, Bethesda, MD 20892 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S106 / S106
页数：1
相关论文
共 50 条
  • [1] Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer.
    Overmoyer, B
    Silverman, P
    Leeming, R
    Shenk, R
    Lyons, J
    Ziats, N
    Jesberger, J
    Dumadag, L
    Remick, S
    Chen, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 58S - 58S
  • [2] A phase II trial of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
    Lu, YS
    Kuo, SH
    Su, WP
    Yang, CH
    Hsu, C
    Yang, TL
    Huang, CS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 93S - 93S
  • [3] A phase II trial of Neoadjuvant docetaxel and capecitabine for locally advanced breast cancer
    Lebowitz, PF
    Eng-Wong, J
    Swain, SM
    Berman, A
    Merino, MJ
    Chow, CK
    Venzon, D
    Zia, F
    Danforth, D
    Liu, E
    Zujewski, J
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (20) : 6764 - 6769
  • [4] Phase II trial of neoadjuvant docetaxel and carboplatin with filgrastim (G-CSF) support in patients with locally advanced breast cancer.
    Karmarkar, S
    Jones, D
    Hatch, S
    Klementich, F
    Ansari, K
    Grube, B
    Chao, C
    Townsend, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 74S - 74S
  • [5] Phase II study of neoadjuvant therapy with epirubicin and docetaxel for women with locally advanced breast cancer.
    Holter, JL
    Tfayli, A
    Venkattapa, S
    Bova, A
    Howard, O
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 98S - 98S
  • [6] A Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Docetaxel and Gemcitabine in Locally Advanced Breast Cancer
    Jeon, Ye Won
    Kim, Tae Hyun
    Youn, Hyun Jo
    Han, Sehwan
    Jung, Yongsik
    Gwak, Geumhee
    Park, Young Sam
    Kim, Jeong Soo
    Suh, Young Jin
    [J]. JOURNAL OF BREAST CANCER, 2017, 20 (04) : 340 - 346
  • [7] A phase II trial of docetaxel (taxotere) in combination with epirubicin as neoadjuvant chemotherapy in patients with locally advanced breast cancer
    Fried, G
    Zidan, J
    Epelbaum, R
    Keren-Rosenberg, S
    Basher, W
    Steckelman, I
    Kogan, F
    Haim, N
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S69 - S70
  • [8] Induction of the prosurvival secretory clusterin protein as a marker of response after neoadjuvant docetaxel, with or without bevacizumab in patients with locally advanced breast cancer.
    Overmoyer, B
    Silverman, P
    Leeming, R
    Shenk, R
    Dumadag, L
    Beman, M
    Chen, H
    Boothman, D
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S253 - S253
  • [9] Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial
    Jakobsen, Anders
    Andersen, Fahimeh
    Fischer, Anders
    Jensen, Lars H.
    Jorgensen, Jens C. R.
    Larsen, Ole
    Lindebjerg, Jan
    Ploen, John
    Rafaelsen, Soren R.
    Vilandt, Jesper
    [J]. ACTA ONCOLOGICA, 2015, 54 (10) : 1747 - 1753
  • [10] A Phase II Trial of Neoadjuvant Gemcitabine, Epirubicin, and Docetaxel as Primary Treatment of Patients With Locally Advanced or Inflammatory Breast Cancer
    Yardley, Denise A.
    Peacock, Nancy W.
    Dickson, Natalie R.
    White, Melissa B.
    Vazquez, Elizabeth R.
    Foust, John T.
    Grapski, Richard
    Hendricks, Linda K.
    Scott, William L.
    Hainsworth, John D.
    [J]. CLINICAL BREAST CANCER, 2010, 10 (03) : 217 - 223
12345